Stock Events

Stock Events

Mesoblast 

$12.41
106
+$0.46+3.85%Tuesday 20:00
+$0.07+0.6%Tuesday 23:42After hours

Statistics

Day High
12.42
Day Low
12.4
52W High
21.5
52W Low
11.89
Volume
5,656
Avg. Volume
-
Mkt Cap
1.61B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Aug 26Expected
Q4 2023
Q1 2024
Q2 2024
Q4 2024
Q2 2025
Q4 2025
Q2 2026
-0.11
-0.08
-0.04
0
Expected EPS
-0.01055
Actual EPS
-0.013

Financials

-47.82%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
120.25MRevenue
-57.5MNet Income

Analyst Ratings

$39.00Average Price Target
The highest estimate is ⁦39.00⁩.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MESO. It's not an investment recommendation.
Tesla
11
TSLA
National Australia Bank Limited
11
NAB.AU
Apple
10
AAPL
Bitcoin
10
BTC.CRYPTO

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biolife Solutions
BLFS
Mkt Cap1.82B
BioLife Solutions provides bioproduction tools and services, including cell and gene therapy solutions, which are essential for companies like Mesoblast, making them a competitor in the supply chain.
Fate Therapeutics
FATE
Mkt Cap277.98M
Fate Therapeutics is focused on developing programmed cellular immunotherapies for cancer and immune disorders, competing with Mesoblast in the cell therapy and regenerative medicine market.
CRISPR Therapeutics
CRSP
Mkt Cap5.36B
CRISPR Therapeutics is engaged in gene editing and gene-based medicine, competing with Mesoblast in the broader regenerative medicine and cell therapy sector.
Vericel
VCEL
Mkt Cap2.06B
Vericel Corporation focuses on autologous cell therapies for the treatment of patients with serious diseases and conditions, directly competing with Mesoblast's therapeutic areas.
NovoCure
NVCR
Mkt Cap1.74B
NovoCure operates in the oncology sector with a novel therapy, competing indirectly with Mesoblast by targeting some of the same diseases but with different therapeutic approaches.
Biomarin Pharmaceutical
BMRN
Mkt Cap11.07B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, competing with Mesoblast in the broader market for novel therapies.

About

Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
Show More
CEO
Silviu Itescu
Employees
108
Country
Australia
ISIN
US5907174016
WKN
000A4004R

Listings

MU
DE
LWB.MU
STU
DE
LWB.STU
STU
DE
LWB1.STU
MU
DE
LWB1.MU

0 Comments

Share your thoughts

FAQs

What is Mesoblast stock price today?▼
The current price of MESO is $12.41 USD — it has increased by +3.85% in the past 24 hours. Watch Mesoblast stock price performance more closely on the chart.
What is Mesoblast stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Mesoblast stocks are traded under the ticker MESO.
Is Mesoblast stock price growing?▼
MESO stock has fallen by -10.01% compared to the previous week, the month change is a -19.83% fall, over the last year Mesoblast has showed a -32.44% decrease.
What is Mesoblast market cap?▼
Today Mesoblast has the market capitalization of 1.61B
When is the next Mesoblast earnings date?▼
Mesoblast is going to release the next earnings report on March 4, 2027.
What were Mesoblast earnings last quarter?▼
MESO earnings for the last quarter are -0.01 USD per share, whereas the estimation was -0.01 USD resulting in a -23.22% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Mesoblast revenue for the last year?▼
Mesoblast revenue for the last year amounts to 120.25M USD.
What is Mesoblast net income for the last year?▼
MESO net income for the last year is -57.5M USD.
How many employees does Mesoblast have?▼
As of October 21, 2026, the company has 108 employees.
In which sector is Mesoblast located?▼
Mesoblast operates in the Health & Wellness sector.
When did Mesoblast complete a stock split?▼
The last stock split for Mesoblast was on January 10, 2024 with a ratio of 1:2.
Where is Mesoblast headquartered?▼
Mesoblast is headquartered in Melbourne, Australia.